BRAF and melanoma: Experiments illustrate that the combination of SORAFENIB and DASATINIB has a synergistic effect on melanoma cell line A2058, and inhibition of BRAF and KIT, the corresponding targets of SORAFENIB, reduces melanoma cell proliferation (Quattrini et al. 2019, Wang et al. 2021).